Register entry
- Registered sites
- 0
- Active NDC listings
- 9
- Live patents
- 20
- Countries
- 0
Catalogue
Drug listings by form and route
99 active NDC listings: 9 human prescription drug. By marketing category: NDA 8, BLA 1.
| Dosage form | NDCs |
|---|---|
| injection, solution | 3 |
| implant | 2 |
| tablet | 2 |
| injection | 1 |
| injection, solution, concentrate | 1 |
| Route | NDCs |
|---|---|
| intrathecal | 3 |
| intravenous | 2 |
| oral | 2 |
| subcutaneous | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| tersera therapeutics llc | 9 |
Exclusivity
Patents and exclusivities
20| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7563801 | VARUBIrolapitant hydrochloride | product | Apr 2027 |
| 7981905 | VARUBIrolapitant hydrochloride | use | Apr 2027 |
| 8178550 | VARUBIrolapitant hydrochloride | substance, product | Apr 2027 |
| 8404702 | VARUBIrolapitant hydrochloride | use | Apr 2027 |
| 7553840 | XERMELOtelotristat etiprate | substance | Dec 2027 |
| 7968559 | XERMELOtelotristat etiprate | use | Dec 2027 |
| 7049320 | VARUBIrolapitant hydrochloride | substance, product | Aug 2028 |
| 8653094 | XERMELOtelotristat etiprate | use | Dec 2028 |
| 8470842 | VARUBIrolapitant hydrochloride | use | Jan 2029 |
| 8361500 | VARUBIrolapitant hydrochloride | product | Oct 2029 |
| 8545879 | QMIIZ ODTmeloxicam | product | Aug 2030 |
| 8193204 | XERMELOtelotristat etiprate | substance | Feb 2031 |
| 7709493 | XERMELOtelotristat etiprate | substance | Feb 2031 |
| 9101615 | VARUBIrolapitant hydrochloride | use | Jul 2032 |
Catalogue
Marketed products
9| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| MARGENZA | margetuximab-cmkb | injection, solution, concentrate, intravenous | 70720-022BLA |
| PRIALT | ziconotide acetate | injection, solution, intrathecal | 70720-720NDA |
| PRIALT | ziconotide acetate | injection, solution, intrathecal | 70720-722NDA |
| PRIALT | ziconotide acetate | injection, solution, intrathecal | 70720-723NDA |
| QUZYTTIR | Cetirizine Hydrochloride | injection, intravenous | 70720-100NDA |
| Varubi | rolapitant | tablet, oral | 70720-101NDA |
| Xermelo | telotristat ethyl | tablet, oral | 70720-125NDA |
| ZOLADEX | goserelin | implant, subcutaneous | 70720-950NDA |
| ZOLADEX | goserelin | implant, subcutaneous | 70720-951NDA |
Compare
Other companies listing ziconotide acetate
- ESTEVE PHARMACEUTICALS, S.A.0 sites · 8 NDC
Enquiry
Common questions
- Is TerSera Therapeutics LLC FDA approved?
- TerSera Therapeutics LLC holds no registered establishment of its own; 9 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does TerSera Therapeutics LLC make?
- 9 products are listed under TerSera Therapeutics LLC in the openFDA NDC Directory, most often as injection, solution; implant; tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.